Citadel Advisors’s Regeneron Pharmaceuticals REGN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $133M | Sell |
172,400
-101,600
| -37% | -$77.8M | 0.02% | 639 |
|
|
2025
Q4 | $211M | Buy |
274,000
+109,300
| +66% | +$74.2M | 0.03% | 464 |
|
|
2025
Q3 | $92.6M | Sell |
164,700
-33,100
| -17% | -$18.7M | 0.01% | 899 |
|
|
2025
Q2 | $104M | Buy |
197,800
+8,400
| +4% | +$4.69M | 0.02% | 741 |
|
|
2025
Q1 | $120M | Sell |
189,400
-17,900
| -9% | -$12.3M | 0.02% | 589 |
|
|
2024
Q4 | $148M | Buy |
207,300
+6,400
| +3% | +$5.37M | 0.03% | 532 |
|
|
2024
Q3 | $211M | Buy |
200,900
+58,200
| +41% | +$64.8M | 0.04% | 348 |
|
|
2024
Q2 | $150M | Sell |
142,700
-68,700
| -32% | -$66.6M | 0.03% | 468 |
|
|
2024
Q1 | $203M | Sell |
211,400
-81,500
| -28% | -$77.5M | 0.04% | 364 |
|
|
2023
Q4 | $257M | Buy |
292,900
+18,000
| +7% | +$14.8M | 0.05% | 261 |
|
|
2023
Q3 | $226M | Buy |
274,900
+13,500
| +5% | +$10.6M | 0.05% | 279 |
|
|
2023
Q2 | $188M | Sell |
261,400
-210,000
| -45% | -$162M | 0.04% | 348 |
|
|
2023
Q1 | $387M | Sell |
471,400
-101,500
| -18% | -$76.6M | 0.09% | 134 |
|
|
2022
Q4 | $413M | Sell |
572,900
-30,700
| -5% | -$22.7M | 0.1% | 143 |
|
|
2022
Q3 | $416M | Buy |
603,600
+306,600
| +103% | +$193M | 0.09% | 121 |
|
|
2022
Q2 | $176M | Buy |
297,000
+51,200
| +21% | +$33.3M | 0.05% | 320 |
|
|
2022
Q1 | $172M | Sell |
245,800
-137,400
| -36% | -$86.9M | 0.04% | 409 |
|
|
2021
Q4 | $242M | Sell |
383,200
-9,600
| -2% | -$5.9M | 0.05% | 279 |
|
|
2021
Q3 | $238M | Buy |
392,800
+55,300
| +16% | +$34.3M | 0.05% | 287 |
|
|
2021
Q2 | $189M | Sell |
337,500
-88,900
| -21% | -$45M | 0.04% | 343 |
|
|
2021
Q1 | $202M | Buy |
426,400
+101,100
| +31% | +$49.2M | 0.05% | 282 |
|
|
2020
Q4 | $157M | Buy |
325,300
+93,400
| +40% | +$50.4M | 0.04% | 348 |
|
|
2020
Q3 | $130M | Sell |
231,900
-86,500
| -27% | -$52.4M | 0.04% | 337 |
|
|
2020
Q2 | $199M | Sell |
318,400
-37,400
| -11% | -$21.2M | 0.07% | 183 |
|
|
2020
Q1 | $174M | Sell |
355,800
-112,400
| -24% | -$46.4M | 0.08% | 171 |
|
|
2019
Q4 | $176M | Buy |
468,200
+129,800
| +38% | +$43.7M | 0.08% | 206 |
|
|
2019
Q3 | $93.9M | Buy |
338,400
+34,600
| +11% | +$10.2M | 0.04% | 429 |
|
|
2019
Q2 | $95.1M | Sell |
303,800
-124,900
| -29% | -$41.6M | 0.04% | 418 |
|
|
2019
Q1 | $176M | Buy |
428,700
+87,200
| +26% | +$35.9M | 0.09% | 170 |
|
|
2018
Q4 | $128M | Sell |
341,500
-35,700
| -9% | -$13.1M | 0.07% | 249 |
|
|
2018
Q3 | $152M | Buy |
377,200
+125,300
| +50% | +$47.7M | 0.07% | 262 |
|
|
2018
Q2 | $86.9M | Sell |
251,900
-10,300
| -4% | -$3.22M | 0.04% | 424 |
|
|
2018
Q1 | $90.3M | Sell |
262,200
-72,400
| -22% | -$25.2M | 0.05% | 359 |
|
|
2017
Q4 | $126M | Buy |
334,600
+47,400
| +17% | +$19.2M | 0.08% | 247 |
|
|
2017
Q3 | $128M | Sell |
287,200
-40,800
| -12% | -$19.4M | 0.1% | 175 |
|
|
2017
Q2 | $161M | Buy |
328,000
+122,700
| +60% | +$53.7M | 0.14% | 113 |
|
|
2017
Q1 | $79.6M | Buy |
205,300
+26,200
| +15% | +$9.71M | 0.07% | 258 |
|
|
2016
Q4 | $65.7M | Sell |
179,100
-75,600
| -30% | -$28.7M | 0.07% | 286 |
|
|
2016
Q3 | $102M | Sell |
254,700
-26,700
| -9% | -$10.7M | 0.1% | 158 |
|
|
2016
Q2 | $98.3M | Buy |
281,400
+72,700
| +35% | +$28M | 0.11% | 150 |
|
|
2016
Q1 | $75.2M | Buy |
208,700
+12,100
| +6% | +$4.99M | 0.09% | 187 |
|
|
2015
Q4 | $107M | Sell |
196,600
-51,200
| -21% | -$27.7M | 0.12% | 180 |
|
|
2015
Q3 | $115M | Buy |
247,800
+71,200
| +40% | +$38.2M | 0.11% | 175 |
|
|
2015
Q2 | $90.1M | Buy |
176,600
+2,200
| +1% | +$1.07M | 0.08% | 269 |
|
|
2015
Q1 | $78.7M | Sell |
174,400
-21,300
| -11% | -$9.03M | 0.07% | 297 |
|
|
2014
Q4 | $80.3M | Buy |
195,700
+50,100
| +34% | +$19.7M | 0.08% | 265 |
|
|
2014
Q3 | $52.5M | Buy |
145,600
+14,200
| +11% | +$4.76M | 0.06% | 388 |
|
|
2014
Q2 | $37.1M | Buy |
131,400
+2,200
| +2% | +$652K | 0.04% | 500 |
|
|
2014
Q1 | $38.8M | Sell |
129,200
-43,000
| -25% | -$13.2M | 0.05% | 496 |
|
|
2013
Q4 | $47.4M | Sell |
172,200
-23,200
| -12% | -$6.67M | 0.06% | 383 |
|
|
2013
Q3 | $61.1M | Buy |
195,400
+54,900
| +39% | +$14.4M | 0.09% | 231 |
|
|
2013
Q2 | $31.6M | Buy |
+140,500
| New | +$32.7M | 0.05% | 424 |
|
Other funds holding REGN
VCM
N
Citadel Advisors's REGN Position: Q1 2026 in Review
Citadel Advisors reduced its Regeneron Pharmaceuticals (REGN) stake by 67% in Q1 2026, selling an estimated $74.5M and leaving 47,687 shares worth $36.8M. The position accounts for 0.01% of the portfolio, ranked #1652.
Citadel Advisors first reported a position in REGN in Q2 2013 and has held it in 51 quarters since. The position peaked at $357M in Q2 2025. 1,392 funds tracked by Wall St. Rank hold REGN as of Q1 2026.
- Citadel Advisors held 47,687 shares of Regeneron Pharmaceuticals worth $36.8M as of Q1 2026.
- Citadel Advisors sold 97,283 Regeneron Pharmaceuticals shares in Q1 2026, an estimated $74.5M.
- Regeneron Pharmaceuticals made up 0.01% of Citadel Advisors's portfolio in Q1 2026, its #1652 holding.
- Citadel Advisors first reported a position in Regeneron Pharmaceuticals in Q2 2013 and has held it in 51 quarters since.
- Citadel Advisors's Regeneron Pharmaceuticals position peaked at $357M in Q2 2025.
- 1,392 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2026.
Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.